Published in J Virol on May 01, 2004
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A (2007) 2.69
Crystal structure of west nile virus envelope glycoprotein reveals viral surface epitopes. J Virol (2006) 2.20
Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol (2006) 1.91
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol (2004) 1.25
Report of an NIAID workshop on dengue animal models. Vaccine (2010) 1.23
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J (2011) 1.17
The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis (2010) 0.99
Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody. BMC Microbiol (2013) 0.87
The role of the mosquito in a dengue human infection model. J Infect Dis (2014) 0.77
Human Monoclonal Fab Antibodies Against West Nile Virus and its Neutralizing Activity Analyzed in Vitro and in Vivo. J Antivir Antiretrovir (2009) 0.75
Critical Role of Kupffer Cell CD89 Expression in Experimental IgA Nephropathy. PLoS One (2016) 0.75
Flavivirus genome organization, expression, and replication. Annu Rev Microbiol (1990) 14.20
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature (1995) 12.25
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A (1991) 5.94
High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem (2000) 5.18
Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol (1991) 4.63
Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg (1982) 4.04
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis (1997) 3.88
Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology (1994) 3.82
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology (1998) 3.80
Proteolytic activation of tick-borne encephalitis virus by furin. J Virol (1997) 3.78
Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol (1999) 3.44
Molecular evolution and phylogeny of dengue-4 viruses. J Gen Virol (1997) 3.30
The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol (1992) 3.19
Infectious RNA transcribed from stably cloned full-length cDNA of dengue type 4 virus. Proc Natl Acad Sci U S A (1991) 2.97
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci U S A (1991) 2.60
Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J Virol (1989) 2.59
Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg (1982) 2.41
Cell-associated West Nile flavivirus is covered with E+pre-M protein heterodimers which are destroyed and reorganized by proteolytic cleavage during virus release. J Virol (1989) 2.38
Structure of human immunoglobulin gamma genes: implications for evolution of a gene family. Cell (1982) 2.32
Length distribution of CDRH3 in antibodies. Proteins (1993) 2.12
Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg (1987) 2.07
Isolation and expression of functional high-affinity Fc receptor complementary DNAs. Science (1989) 2.06
Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol (1990) 2.05
Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg (1985) 2.04
Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol (1988) 2.02
In vitro processing of dengue virus structural proteins: cleavage of the pre-membrane protein. J Virol (1989) 2.02
Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc Natl Acad Sci U S A (1993) 2.01
Immune enhancement of viral infection. Prog Allergy (1982) 1.94
In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A (1994) 1.93
Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol (1988) 1.83
Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies. J Virol (2002) 1.69
Epitope mapping of flavivirus glycoproteins. Adv Virus Res (1986) 1.67
Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol (1986) 1.67
Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol (1984) 1.58
Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol (1999) 1.56
Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice. J Gen Virol (1986) 1.55
A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology (1983) 1.53
Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol (2000) 1.48
A directory of human germ-line V kappa segments reveals a strong bias in their usage. Eur J Immunol (1994) 1.44
Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci U S A (1994) 1.40
A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J Virol (2003) 1.31
Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology (1991) 1.29
Dengue in Greece in 1927 and 1928 and the pathogenesis of dengue hemorrhagic fever: new data and a different conclusion. Am J Trop Med Hyg (1986) 1.26
Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. Proc Natl Acad Sci U S A (1991) 1.23
A large section of the gene locus encoding human immunoglobulin variable regions of the kappa type is duplicated. J Mol Biol (1985) 1.18
Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J Virol (1991) 1.17
High level synthesis of immunoglobulins in Chinese hamster ovary cells. J Immunol (1990) 1.16
Tick-borne encephalitis virus envelope protein E-specific monoclonal antibodies for the study of low pH-induced conformational changes and immature virions. Arch Virol (1995) 1.13
Potential of primate monoclonal antibodies to substitute for human antibodies: nucleotide sequence of chimpanzee Fab fragments. Hum Antibodies Hybridomas (1990) 1.04
The V kappa genes of the L regions and the repertoire of V kappa gene sequences in the human germ line. Eur J Immunol (1993) 1.03
Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. J Virol (1998) 1.02
Identification of an antigenic and genetic variant of dengue-4 virus from the Caribbean. Am J Trop Med Hyg (1986) 1.02
Rapid focus reduction neutralization test of Japanese encephalitis virus in microtiter system. Brief report. Arch Virol (1985) 0.98
Binding of an antibody mimetic of the human low density lipoprotein receptor to apolipoprotein E is governed through electrostatic forces. Studies using site-directed mutagenesis and molecular modeling. J Biol Chem (2000) 0.91
Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A (1993) 0.91
Influence of the human high-affinity IgG receptor FcgammaRI (CD64) on residual infectivity of neutralized dengue virus. Virology (1999) 0.87
pFab-CMV, a single vector system for the rapid conversion of recombinant Fabs into whole IgG1 antibodies. Immunotechnology (1999) 0.86
Further characterization of the fate of human monoclonal antibodies in rhesus monkeys. Hybridoma (1988) 0.82
Nucleotide sequence of chimpanzee Fc and hinge regions. Mol Immunol (1991) 0.82
The effect of dihydrofolate reductase-mediated gene amplification on the expression of transfected immunoglobulin genes. J Immunol (1987) 0.79
Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins. J Immunol Methods (1995) 0.79
Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A (2002) 5.81
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol (2003) 4.42
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Hepatitis E virus. Rev Med Virol (2003) 3.34
Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A (2004) 3.16
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A (2007) 2.69
Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis (2009) 2.62
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A (2002) 2.04
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology (2004) 2.01
Hepatitis E. N Engl J Med (2012) 1.99
Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A (2010) 1.96
Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A (2004) 1.96
The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A (2003) 1.93
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.83
Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc Natl Acad Sci U S A (2011) 1.81
Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis (2008) 1.75
A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. J Virol (2006) 1.74
The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol (2009) 1.71
In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J Virol (2004) 1.66
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol (2010) 1.55
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology (2008) 1.55
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
The open reading frame 3 gene of hepatitis E virus contains a cis-reactive element and encodes a protein required for infection of macaques. J Virol (2005) 1.50
Running like water--the omnipresence of hepatitis E. N Engl J Med (2004) 1.49
ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro. J Virol (2006) 1.47
Hepatitis E virus in rats, Los Angeles, California, USA. Emerg Infect Dis (2011) 1.45
High prevalence of hepatitis E antibodies in pregnant Egyptian women. Trans R Soc Trop Med Hyg (2005) 1.40
Thermal stability of hepatitis E virus. J Infect Dis (2005) 1.39
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog (2012) 1.35
Hidden danger: the raw facts about hepatitis E virus. J Infect Dis (2010) 1.35
Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol (2008) 1.33
Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. J Virol (2010) 1.32
Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci U S A (2005) 1.29
Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay. J Gen Virol (2006) 1.29
Comparative evolution of GII.3 and GII.4 norovirus over a 31-year period. J Virol (2011) 1.28
Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress. J Virol (2009) 1.27
B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci U S A (2010) 1.26
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol (2004) 1.25
Apolipoprotein c1 association with hepatitis C virus. J Virol (2008) 1.24
In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology (2011) 1.23
Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun (2009) 1.22
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis (2010) 1.21
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J (2011) 1.17
Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J Virol (2007) 1.16
Epidemic of hepatitis E in a military unit in Abbotrabad, Pakistan. Am J Trop Med Hyg (2002) 1.15
Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles. Clin Vaccine Immunol (2009) 1.15
Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc Natl Acad Sci U S A (2012) 1.15
An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. Vaccine (2004) 1.15
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci U S A (2009) 1.14
High prevalence of hepatitis E antibodies among Danish prisoners and drug users. J Med Virol (2002) 1.14
Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities. Trans R Soc Trop Med Hyg (2005) 1.12
bla(NDM-1)-positive Klebsiella pneumoniae from environment, Vietnam. Emerg Infect Dis (2012) 1.12
Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis (2011) 1.10
In vitro and in vivo mutational analysis of the 3'-terminal regions of hepatitis e virus genomes and replicons. J Virol (2005) 1.09
Characterization of self-assembled virus-like particles of rat hepatitis E virus generated by recombinant baculoviruses. J Gen Virol (2011) 1.09
Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc Natl Acad Sci U S A (2012) 1.07
Spatial configuration of hepatitis E virus antigenic domain. J Virol (2010) 1.05
A simple vector system to improve performance and utilisation of recombinant antibodies. BMC Biotechnol (2006) 1.05
Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin Infect Dis (2006) 1.04